ArticleRenal failure2025
Risk factors of poor outcomes in ANCA-associated vasculitis: a single-center study.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAnti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare disease with high rate of end-stage kidney disease (ESKD) and mortality. We aimed to investigate the risk factors for ESKD and/or death in AAV patients.
methodsSeventy-eight AAV patients diagnosed from November 2013 to December 2022 were included. Study endpoints included ESKD or death and composite endpoints. Cox regression models were used to adjust for potential baseline confounders.
resultsAmong the 78 cases, there were 16 cases of ESKD, 15 cases of death, and 27 cases of composite endpoint during follow-up. After adjusting for baseline characteristics, baseline blood urea nitrogen (BUN) level (adjusted hazard ratio [HR] 1.07, 95%Cl 1.04-1.10) was an independent risk factor for composite endpoints (ESKD and/or death) in AAV patients. ROC curve analysis showed that the optimal cutoff of BUN level was 19.5 mmol/L for ESKD and death (AUC: 0.760; 95% CI: 0.65-0.87). Baseline BUN levels (HR per 1 mmol/L: 1.09, 95% CI 1.05-1.23) and white blood cell (WBC) counts (HR per 1,000/μL: 1.22, 95% CI 1.07-1.40) were independent risk factors for ESKD in AAV. Cardiovascular involvement (HR 8.74, 95%Cl 2.20-34.73), NLR (HR 1.04, 95%Cl 1.01-1.08), and antiplatelet drug use (HR 6.79, 95%Cl 1.33-34.62) were independent risk factors for death in AAV.
conclusionsThese findings suggest that high baseline BUN level was an independent predictor for ESKD and/or death in AAV patients, even after correction for co-founders including Scr. BUN might constitute an independent, easily available and important parameter for risk stratification in AAV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.